Authors

Latest:

Dr Strosberg on Research Clarifying the Role of Obrixtamig in SCLC and Other Neuroendocrine Cancers

Jonathan Strosberg, MD, discusses how the phase 2 DAREON-5 trial could address questions about the use of DLL3/CD3-targeted agents in SCLC and other NECs.

Jonathan R. Strosberg, MD, Moffitt Cancer Center

Jonathan Riess, MD

Latest:

Dr Riess on Sequencing Considerations for KRAS and BRAF Inhibitors in NSCLC

Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

Latest:

Data From the FURTHER Trial in NSCLC With EGFR PACC Mutations

Panelists discuss how the FURTHER trial demonstrated firmonertinib’s efficacy and safety in patients with PACC mutations.

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center

Jonathan S. Batchelor

Latest:

Flaxseed Ineffective in Controlling Hot Flashes

Flaxseed had no effect on reducing hot flashes in postmenopausal women who reported experiencing 28 or more hot flashes per week.

Jonathan S. Berek, MD

Latest:

Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian Cancer

Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.

Jonathan S. Zager, MD, Moffitt Cancer Center

Jonathan Strosberg, MD

Latest:

Dr. Strosberg Discusses Updates From the NETTER-1 Study

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses updates from the NETTER-1 study in patients with neuroendocrine tumors (NETs).

Jonathan Strosberg, MD, Moffitt

Jonathan Ticku, MD

Latest:

Cloud Computing for Fellows

Cloud computing refers to Web-based programs that allow the user to store information in a central location, typically not the device being used to access the information (such as your laptop, desktop PC, or iPad).

Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center

Latest:

NRG1 Fusions in Solid Tumors: The CRESTONE Trial

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Jonathan Tward, MD, PhD

Latest:

Dr. Tward on Abbreviated Course ADT for Prostate Cancer

Jonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.

Jonathan W. Friedberg, MD, MMSc

Latest:

Rituximab Sets the Pace in Changing Lymphoma Landscape

Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.

Jonathan W. Friedberg, MD, University of Rochester

Jonathan W. Goldman, MD

Jonathan W. Goldman, MD, is a professor of medicine in the Hematology/Oncology Division, director of Clinical Trials in Thoracic Oncology, and associate director of Early Drug Development at UCLA Medical Center in California.

Latest:

Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD

Jonathan W. Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET protein–overexpressing, nonsquamous, EGFR wild-type NSCLC.

Jonathan W. Riess, MD, MS, UC Davis Comprehensive Cancer Center

Latest:

Experts on the Management of Diarrhea Associated With EGFR TKIs

Zosia Piotrowska, MD, Jonathan Riess, MD, MS, Gregory Riely, MD, Emily Skotte, MSN, APRN, ACNP-BC, and Amanda Cass, PharmD, BCPS, discuss the management of diarrhea as an adverse effect associated with EGFR TKIs.

Jonathon B. Cohen, MD

Latest:

Dr Cohen on Available Treatments For MCL

Jonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.

Jonathon B. Cohen, MD, MS

Latest:

Dr Cohen on Treatment Considerations for Relapsed/Refractory MCL

Jonathon B. Cohen, MD, MS, discusses treatment considerations for mantle cell lymphoma and the role of pirtobrutinib in the management of this disease.

Jordan Clark

Latest:

Retesting for FLT3 Mutation Status in AML

Jordan Clark, the chief commercial officer at Diaceutics, discusses FLT3 retesting in a relapsed acute myeloid leukemia setting.